Filter Results

Click on a filter below to refine your search. Remove filter to broaden your search.

Your search for XELJANZ returned 12 results.

Sort results:

Hint: If you don't want the words you enter to be searched for separately, use quotation marks to find people or exact phrases. See our Search Help section for more hints.


Drug Monograph

Tofacitinib 5mg tabs.

Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.

Xeljanz Approved for Rheumatoid Arthritis

MPR Drug News | November 7, 2012

Pfizer announced that the FDA has approved Xeljanz (tofacitinib citrate) tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had inadequate response or intolerance to methotrexate.

FDA Approves Additional Labeling for Xeljanz

MPR Drug News | November 19, 2013

Pfizer announced that the FDA has approved the supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) to include additional patient-reported outcomes data in the label.

Xeljanz Label Gains Radiographic Data Addition

MPR Drug News | February 24, 2014

Pfizer announced that the FDA has approved a sNDA to update the current label of Xeljanz (tofacitinib citrate) tablets to include radiographic data from two Phase 3 studies, ORAL Scan and ORAL Start.

Xeljanz Demonstrates Efficacy in Chronic Plaque Psoriasis

MPR Drug News | March 24, 2014

Pfizer announced results from OPT Compare (A3921080), a Phase 3 study of Xeljanz (tofacitinib) for the treatment of adults with moderate-to-severe chronic plaque psoriasis.

Pfizer's sNDA for Xeljanz Indication Expansion Accepted for Review

MPR Drug News | June 24, 2013

The FDA has accepted Pfizer's sNDA for review for an expanded indication for Xeljanz to include inhibition of progression of structural damage in the label. Xeljanz is a first in its class Janus Kinase inhibitor.

2013 New Products Slideshow

Slideshow | January 7, 2014

Enjoy the year in review of new drug products from 2013

Featured drug products: Adasuve, Adempas, Belviq, Breo Ellipta, Diclegis, Eliquis, Fetzima, Fulyzaq, Giazo, Invokana, Juxtapid, Kazano, Kynamro, Liptruzet, Nesina, Opsumit, Oseni, Oxtellar...

Tofacitinib Slows Joint Damage in Rheumatoid Arthritis

News | January 25, 2013

Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA).

Tofacitinib Improves Rheumatoid Arthritis Treatment Response

News | August 22, 2013

The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs).

Rheumatoid Arthritis Patient Information Fact Sheet

Web | June 21, 2013

This patient information fact sheet provides information on the definition, symptoms, causes, diagnostic tests, treatments and self-help measures for rheumatoid arthritis.

Arthritis Treatments: DMARDS and Other Immune Modulators

Clinical Charts | March 14, 2014

Dosing regimens of DMARDS and other immune modulators used in the treatment of arthritis.

May 2013 New Drug CME/CEU Review

Feature | June 26, 2013

This CME/CEU activity is designed to give clinicians a better understanding of the pharmacology, indications, contraindications, benefits/risk and clinical trials data of a broad spectrum of new agents and those that have been granted a new indication.

Sign Up for Free e-newsletters